Devonian Health GroupDVHGF 49 PB Ratio is 3.38 as of Jul. 03, 2026, which is 25% above its 10-year median of 2.71. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,228 Biotechnology companies, Devonian Health Group ranks better than 52.36% on this metric.
The historical rank and industry rank for Devonian Health Group's PB Ratio or its related term are showing as below:
DVHGF'
s PB Ratio Range Over the Past 10 Years
Min: 0.75 Med: 2.71 Max: 61.07
Current: 3.24
During the past 12 years, Devonian Health Group's highest PB Ratio was 61.07. The lowest was 0.75. And the median was 2.71.
DVHGF's PB Ratio is ranked better than 52.36% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs DVHGF: 3.24
During the past 12 months, Devonian Health Group's average Book Value Per Share Growth Rate was -48.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.00% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Devonian Health Group was 174.50% per year. The lowest was -50.90% per year. And the median was -4.60% per year.
Back to Basics: PB Ratio
Devonian Health Group (OTCPK:DVHGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Devonian Health Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Devonian Health Group (DVHGF) has a PB Ratio of 3.38 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Devonian Health Group and its competitors. This is 25% above median its historical median of 2.71. Over the past decade, Devonian Health Group's PB Ratio has ranged from 0.75 to 61.07. According to the industry distribution chart, Devonian Health Group ranks #585 out of 1228 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Devonian Health Group's PB Ratio too high?
Devonian Health Group's current PB Ratio of 3.38 is 25% above median its 10-year median of 2.71. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 61.07. The Biotechnology industry median PB Ratio is 2.97. Devonian Health Group's value of 3.38 is 13.8% above this industry median. Based on the distribution chart, Devonian Health Group ranks #585 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #585 out of 1228 companies for PB Ratio. This puts Devonian Health Group in the upper half of its industry. The industry median PB Ratio is 2.97. Devonian Health Group's value of 3.38 is 13.8% above this benchmark. Historically, Devonian Health Group's own PB Ratio has ranged from 0.75 to 61.07 over the past decade. While the company's 10-year median is 2.71 vs. the industry median of 2.97, Devonian Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devonian Health Group's current PB Ratio of 3.38 is 13.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Devonian Health Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current PB Ratio is 3.38, which is 25% above median its own 10-year median of 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current PB Ratio is 3.38, which is 25% above median its 10-year median of 2.71 and 13.8% above the Biotechnology industry median of 2.97. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current PB Ratio is 3.38 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
PB Ratio: 3.38 (25% above median its 10-year median of 2.71)
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
Industry Position: 13.8% above the Biotechnology median (#585 of 1228)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
